Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials
Aditya Karthikeyan, Avrohom Karp, Maisha Maliha, Amrin Kharawala, Sridhar Mangalesh, Priyansh Shah, Vishakha Modak, Adir Alper, Apoorva Doshi, Hamsa Murli, Vikyath Satish, Kuan-Yu Chi, Robert T Faillace · 2026
Read Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials by Aditya Karthikeyan, Avrohom Karp, Maisha Maliha, Amrin Kharawala, Sridhar Mangalesh, Priyansh Shah, Vishakha Modak, Adir Alper, Apoorva Doshi, Hamsa Murli, Vikyath Satish, Kuan-Yu Chi, Robert T Faillace (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13326082.txt.
Description
Pill forms of a strong cholesterol drug class are pooled by Aditya Karthikeyan and co-authors in a 2026 review. Shots in this class cut bad cholesterol deeply but demand injections. Trials of oral versions against placebo were gathered through early 2026.
Adults with artery disease, high risk, or statin intolerance form the trial base, all on standard background care. Outcomes span bad cholesterol and related fats, plus harms and dropouts. A pill that matches the shots could widen use hugely, since many patients dodge injections. The pooled numbers tell doctors how much of the benefit survives the switch to oral dosing.
Catalog record
| CREATOR | Aditya Karthikeyan, Avrohom Karp, Maisha Maliha, Amrin Kharawala, Sridhar Mangalesh, Priyansh Shah, Vishakha Modak, Adir Alper, Apoorva Doshi, Hamsa Murli, Vikyath Satish, Kuan-Yu Chi, Robert T Faillace |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |